Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
Ian M. McElree(Vanderbilt University Medical Center), Vignesh T. Packiam(Rutgers, The State University of New Jersey), Michael A. O’Donnell(University of Iowa Health Care), Paul T. Gellhaus(University of Iowa), Sarah L. Mott(University of Iowa Holden Comprehensive Cancer Center), Kenneth G. Nepple(University of Iowa), Ryan L. Steinberg(University of Iowa), Jordan Richards(University of Iowa), Alexander C. Martin(University of Iowa)
Cited by 0
Related Papers
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer
|The Journal of Urology|2022|71
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer
|Urologic Oncology Seminars and Original Investigations|2022|59
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
|European Urology Oncology|2023|38
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
|British Journal of Urology|2024|27